Evicenter
Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in Pneumococcal disease prevention in adults
Manufacturer
Wyeth Pharmaceutical Division of Wyeth Holdings LLC
Prescribing information
Prevnar 20 (opens in a new tab)
Questions
21
Last updated

All questions

Clinical trials: Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults

5 questions · 3 sources

Interpreting study results

How was Prevnar 20 effectiveness in adults established?

Study results

Prevnar 20 vs Prevnar 13 and PPSV23: how did immune responses compare in adults 60+?

Applies to Pneumococcal vaccine-naive adults 60 years of age and older (Study 1)

Note: Study 1 compared Prevnar 20 with Prevnar 13 for the 13 shared serotypes and with PPSV23 (23-valent pneumococcal polysaccharide vaccine) for the 7 additional serotypes. The label reports each serotype's GMTs and GMT ratio in Table 13.

How was Prevnar 20 effectiveness inferred in adults 18 to 59?

Applies to Pneumococcal vaccine-naive adults 18 through 59 years of age (Study 1 immunobridging)

What immune responses did Prevnar 20 produce in previously vaccinated adults 65+?

Applies to Adults 65 years of age and older previously vaccinated with a pneumococcal vaccine (Study 6)

What did the Prevnar 13 CAPiTA trial show in adults 65 and older?

Applies to Prevnar 13 (13-valent predecessor vaccine) in adults 65 years of age and older (CAPiTA); cited by the label as relevant to Prevnar 20

Note: CAPiTA tested Prevnar 13, the 13-valent predecessor vaccine. In Table 8, the episode columns are the total, Prevnar 13 (n), and placebo (N), followed by vaccine efficacy (VE) with its 95.2% CI.